Statement by Blue Earth Diagnostics on COVID-19 click here for more information

Product Pipeline and Clinical trials


Addressing Unmet Clinical Needs in Molecular Imaging

Blue Earth Diagnostics is committed to transforming the clinical management of patients with cancer. We are focused on developing advanced imaging technologies to address unmet clinical needs. These imaging technologies can help physicians detect cancer and make decisions about patient care.

We conduct scientific studies, called clinical trials, to find better ways to identify the location of cancer in the body. Some of our clinical trials provide information on the benefits, side effects and possible uses for new imaging technologies. Other trials explore new uses for existing imaging technologies. Results from clinical trials are submitted for review to Regulatory Authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These regulatory agencies have strict standards for determining if new imaging technologies or new uses of existing imaging technologies are safe and effective. If a new imaging technology meets these standards, it can be approved and becomes available by prescription.

Patients or their physicians who are interested in participating in Blue Earth Diagnostics’ clinical trials can find further details, including clinical trial locations and contact information, by clicking on these links:


Blue Earth Diagnostics’ commitment is to develop and commercialise innovative radiopharmaceutical agents that inform treatment decisions and to make a meaningful difference for people with cancer, focusing on areas of considerable unmet medical need. Here you can explore details of our research pipeline, arranged by product.

Our Pipeline

Product/Candidate Potential Use Application Preclinical Phase 1 Phase 2 Phase 3 Approved (US) Approved (EU)
Suspected recurrent prostate cancer
PET imaging
Fluciclovine(18F) Brain Metastases PET imaging
rhPSMA-7.3(18F) Prostate cancer PET imaging
rhPSMA* Prostate cancer Radiopharmaceutical Therapy

* Option collaboration